Docetaxel / NK cell Cancer Research Results

docx, Docetaxel: Click to Expand ⟱
Features:
Docetaxel, (brand name Taxotere) is a chemotherapy medication used to treat breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.
Docetaxel is a microtubule-stabilizing agent (taxane). It binds β-tubulin and promotes microtubule polymerization / prevents depolymerization, causing mitotic arrest (G2/M) and downstream cell death.
Clinically important constraints:
-Neutropenia / febrile neutropenia are major dose-limiting toxicities.
-Premedication with dexamethasone is standard to reduce fluid retention and hypersensitivity reactions.
-Metabolism is mainly CYP3A4, so strong CYP3A4 inhibitors/inducers (and grapefruit) can materially change exposure.


Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Microtubule stabilization (β-tubulin) → mitotic spindle dysfunction Microtubule dynamics ↓; mitotic progression fails Also impacts normal proliferating cells P, R Core cytotoxic mechanism Taxane class MOA: stabilizes microtubules and blocks depolymerization, disrupting mitosis.
2 Mitotic arrest (G2/M checkpoint pressure) G2/M arrest ↑; proliferation ↓ Bone marrow / GI epithelium vulnerability ↑ R, G Cell-cycle blockade Mitotic arrest is the key phenotype linking microtubule disruption to cell death outcomes.
3 Intrinsic apoptosis (mitochondrial) secondary to mitotic catastrophe Apoptosis ↑ (context); caspase activation ↑ ↔ / tissue injury possible at high exposure G Death execution Cell death often occurs after prolonged mitotic arrest (mitotic catastrophe → apoptosis).
4 Neutropenia / marrow suppression (on-target toxicity) — Neutrophils ↓; febrile neutropenia risk ↑ R, G Dose-limiting toxicity Major clinical constraint; risk increases with dose and interacting drugs.
5 Hypersensitivity reactions — Hypersensitivity risk ↑ (especially early infusions) P, R Acute infusion risk Premedication is used to reduce frequency/severity of hypersensitivity reactions.
6 Fluid retention / capillary leak tendency — Fluid retention ↑ (can be severe) R, G Key non-hematologic toxicity Dexamethasone premedication is standard to reduce incidence and severity.
7 Combination leverage (sensitization with other agents) Synergy reported in multiple regimens Toxicity may ↑ depending on partner drug G Regimen-driven efficacy Docetaxel is commonly used in multi-agent protocols; outcome is regimen- and tumor-type-specific.
8 Pharmacokinetics (CYP3A4 metabolism) Exposure ↑ with strong CYP3A4 inhibitors; ↓ with inducers Exposure shifts → toxicity/efficacy shifts P, R Interaction driver Docetaxel is primarily cleared by CYP3A4; strong inhibitors can raise levels substantially.
9 Grapefruit / intestinal CYP3A4 inhibition (interaction risk) Potential exposure ↑ (context) Potential toxicity ↑ (context) P, R Diet–drug interaction Grapefruit can inhibit intestinal CYP3A4; docetaxel is a CYP3A4 substrate, so avoidance is commonly advised.
10 Parameter dependence (dose/schedule; weekly vs q3wk) Mechanism constant; tolerability differs by schedule Toxicity profile differs by schedule — Translation constraint Clinical outcomes and toxicity balance are schedule-dependent (protocol-specific).
11 ROS generation (secondary to mitotic stress) ROS ↑ (mitochondrial); lipid peroxidation ↑ (reported) Oxidative injury possible R, G Stress amplification ROS increase is secondary to mitotic arrest and mitochondrial dysfunction, not a primary redox drug effect.
12 NRF2 antioxidant response NRF2 ↑ (adaptive; reported in resistant models) Protective antioxidant upshift R, G Resistance mechanism NRF2 activation may reduce docetaxel sensitivity by increasing antioxidant capacity (GSH, NQO1, HO-1).

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (binding and immediate microtubule dynamic suppression begins)
  • R: 30 min–3 hr (mitotic checkpoint engagement; acute infusion effects)
  • G: >3 hr (mitotic catastrophe, apoptosis, tissue-level toxicities)
NK cell, NK cell activity: Click to Expand ⟱
Source: HalifaxProj(promote)
Type:
Natural Killer (NK) cells are a type of lymphocyte in the immune system that play a crucial role in the body's defense against tumors and virally infected cells.
NK cells can directly kill cancer cells through the release of cytotoxic granules containing perforin and granzymes. Perforin forms pores in the target cell membrane, allowing granzymes to enter and induce apoptosis (programmed cell death).
NK cells produce various cytokines, such as interferon-gamma (IFN-γ), which can enhance the immune response and promote the activation of other immune cells, including macrophages and T cells.
-Monoclonal Antibodies: Using antibodies that engage NK cells to target and kill cancer cells.
-Cytokine Therapy: Administering cytokines like IL-2 or IL-15 to boost NK cell activity.
Scientific Papers found: Click to Expand⟱
428- Chit,  docx,  CUR,    Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer
- vitro+vivo, Lung, H460 - vitro+vivo, Lung, H1299 - vitro+vivo, Lung, A549 - vitro+vivo, Lung, PC9
MDSCs↓, TregCell↓, IL10↓, NK cell↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Migration ⓘ

TregCell↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↓, 1,   MDSCs↓, 1,   NK cell↑, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: NK cell, NK cell activity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:178  Target#:219  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page